CN1191071C - Product of ginsenoside for improving sextual function - Google Patents
Product of ginsenoside for improving sextual function Download PDFInfo
- Publication number
- CN1191071C CN1191071C CNB021607915A CN02160791A CN1191071C CN 1191071 C CN1191071 C CN 1191071C CN B021607915 A CNB021607915 A CN B021607915A CN 02160791 A CN02160791 A CN 02160791A CN 1191071 C CN1191071 C CN 1191071C
- Authority
- CN
- China
- Prior art keywords
- ginsenoside monomer
- ginsenoside
- monomer
- chinese medicine
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 93
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 93
- 239000000178 monomer Substances 0.000 claims abstract description 93
- 239000003814 drug Substances 0.000 claims abstract description 55
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 23
- 229930182490 saponin Natural products 0.000 claims abstract description 23
- 150000007949 saponins Chemical class 0.000 claims abstract description 23
- 230000036299 sexual function Effects 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000006872 improvement Effects 0.000 claims description 9
- 241000893536 Epimedium Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 235000018905 epimedium Nutrition 0.000 claims description 6
- 235000008434 ginseng Nutrition 0.000 abstract description 17
- 241000208340 Araliaceae Species 0.000 abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 8
- 206010046543 Urinary incontinence Diseases 0.000 abstract description 5
- 210000003127 knee Anatomy 0.000 abstract description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract description 4
- 201000001881 impotence Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 abstract 2
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 2
- 208000021663 Female sexual arousal disease Diseases 0.000 abstract 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 22
- 238000010791 quenching Methods 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 206010024419 Libido decreased Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940046011 buccal tablet Drugs 0.000 description 4
- 239000006189 buccal tablet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a ginsenoside product of monomer compatibility for improving the sextual function. The present invention is characterized in that the ginsenoside product of monomer compatibility comprises ginsenoside monomer Rg3, ginsenoside monomer RH1 and panaxadiol type saponin. The weight compounding ratio of the ginsenoside monomer Rg3 and the ginsenoside monomer RH1 is 1: (0.1-10), and the weight compounding ratio of the ginsenoside monomer Rg3 and the panaxadiol type saponin is 1: (0.1-10). The product can enhance male and female sexual functions and can mainly treat diseases, such as sexual impotence, prospermia, frigidity, soreness and weakness of the waist and the knees, prostatosis, urinary incontinence, etc. without side effect. Compared with the existing medicines for treating the diseases, the present invention has the advantages of favourable effect, short treating time and low expense and has the same efficiency of strengthening a body as the efficiency of ginseng. The present invention enlarges the use reange of ginseng and sufficiently utilizes the specific monomer saponin component in ginseng so that the application of ginseng is wider, more scientific and more reasonable.
Description
Technical field:
The present invention relates to a kind of product that utilizes Radix Ginseng extract to make, particularly a kind of product of ginsenoside monomer compatibility sexual function improvement, be mainly used in and improve man, woman's sexual function, can treat diseases such as sexual impotence, premature ejaculation, hyposexuality, soreness of the waist and knees, prostate, urinary incontinence.
Background technology:
As everyone knows, Radix Ginseng is famous and precious tonic, and its Main Ingredients and Appearance is a saponin, has been found that contained ginsenoside reaches 37 kinds in the Radix Ginseng.At present to ginsenoside's utilization science not also, traditional method is that Radix Ginseng is directly edible or boil and drink as the tonic of building body, make the eater feel scorching, the deficiency of YIN, hyperactivity of fire, can not fully absorb its intrinsic nutrition, be difficult to embody the medical value of Radix Ginseng.
Mainly be to utilize various kinds of drug to alleviate or treat for man, woman's sexual dysfunction at present, as male employed " viagra ", it can only can not play the effect of treatment to this kind disease playing a role for the moment, can not tackle the problem at its root.Take for a long time and can produce the big side effect of tool, impair the health of health.
Summary of the invention:
The product that the purpose of this invention is to provide a kind of ginsenoside monomer compatibility sexual function improvement without any side effects, eutherapeutic, be mainly used in and improve man, woman's sexual function, can treat diseases such as sexual impotence, premature ejaculation, hyposexuality, soreness of the waist and knees, preceding alignment, urinary incontinence, effectively utilized the contained distinctive monomer saponin composition of Radix Ginseng, the application that makes Radix Ginseng is science, economy, rationally more.
Technical solution of the present invention is: a kind of product of ginsenoside monomer compatibility sexual function improvement is characterized in that: it comprises ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: (0.1-10),
Ginsenoside monomer Rg
3: panoxadiol's type saponin is 1: (0.1-10).
This product also comprises ginsenoside monomer Rg
5, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer Rg
5Be 1: (0.1-10).
It also comprises ginsenoside monomer RH this product
2, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer RH
2Be 1: (0.1-10).
It also comprises Chinese medicine extract this product, and described Chinese medicine is: pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, each Chinese medicine extract are equal portions preparation, ginsenoside monomer Rg
3As follows with the weight proportion of Chinese medicine extract:
Ginsenoside monomer Rg
3: Chinese medicine extract is 1: (0.1-10).
It also comprises Chinese medicine extract this product, and described Chinese medicine is: the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, each Chinese medicine extract are equal portions preparation, ginsenoside monomer Rg
3As follows with the weight proportion of Chinese medicine extract:
Ginsenoside monomer Rg
3: Chinese medicine extract is 1: (0.1-10).
The present invention has following advantage: can improve man, woman's sexual function, diseases such as main treatment sexual impotence, premature ejaculation, hyposexuality, soreness of the waist and knees, preceding alignment, urinary incontinence, without any side effects, compare with the medicine of the above-mentioned disease of existing treatment effective, the treatment phase is short, expense is low.The effect of keeping fit the shape body that has Radix Ginseng equally.The present invention has enlarged the scope of application of Radix Ginseng, has made full use of the distinctive saponin monomer composition in the Radix Ginseng, makes the application of Radix Ginseng more extensive, science, more reasonable more.
The specific embodiment:
Employed ginsenoside monomer Rg among the present invention
3, ginsenoside monomer RH
1, ginsenoside monomer Rg
5, ginsenoside monomer RH
2, panoxadiol's type saponin all utilizes biological engineering method to extract from Radix Ginseng, because this method is simple to operate, output capacity is high, makes product cost of the present invention low.Described Radix Ginseng also can be Radix Panacis Quinquefolii or Korean Ginseng or Radix Notoginseng.
The specific embodiment 1:
A, get purity and be 10% ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin carries out compatibility and mixes, its weight ratio is pressed ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: 0.1, ginsenoside monomer Rg
3: panoxadiol's type saponin is to prepare at 1: 0.1.
Get purity and be 10% ginsenoside monomer Rg
3500 grams, ginsenoside monomer RH
150 grams, panoxadiol's type saponin 50 grams, above-mentioned ginsenoside monomer mixture is a pulverulence, adopts the gradient method mix homogeneously to get final product.In order to make this product have better therapeutic effect, can be added with purity and be 10% ginsenoside monomer Rg
550 grams, 10% ginsenoside monomer RH
250 grams.
In product, be added with Chinese medicine extract such as pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, better to treatment insufficiency of kidney-YANG ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 5 grams and the said goods mix homogeneously.
In product, be added with Chinese medicine extract such as the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, better to treatment deficiency of spleen-YANG type ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 5 grams and the said goods mix homogeneously.
Adopt common pharmaceutical technology that said mixture is made oral liquid or buccal tablet or electuary or tablet or drop pill or capsule or close ball.
B, get purity and be 80% ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin carries out compatibility and mixes, its weight ratio is pressed ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: 0.1, ginsenoside monomer Rg
3: panoxadiol's type saponin is to prepare at 1: 0.1.
Get purity and be 80% ginsenoside monomer Rg
362.5 gram, ginsenoside monomer RH
16.25 gram, panoxadiol's type saponin 6.25 grams, above-mentioned ginsenoside monomer mixture is a pulverulence, adopts the gradient method mix homogeneously to get final product.In order to make this product have better therapeutic effect, can be added with purity and be 80% ginsenoside monomer Rg
56.25 gram, 80% ginsenoside monomer RH
26.25 gram.
In product, be added with Chinese medicine extract such as pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, better to treatment insufficiency of kidney-YANG ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 5 grams and the said goods mix homogeneously.
In product, be added with Chinese medicine extract such as the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, better to treatment deficiency of spleen-YANG type ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 5 grams and the said goods mix homogeneously.
Adopt common pharmaceutical technology that said mixture is made oral liquid or buccal tablet or electuary or tablet or drop pill or the close ball of capsule.
In process for preparation, as each monomeric purity difference, available its weight changes adjustment, as long as weight proportion is in institute's restricted portion.
The specific embodiment 2:
Get purity and be 10% ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin carries out compatibility and mixes, its weight ratio is pressed ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: 10, ginsenoside monomer Rg
3: panoxadiol's type saponin is to prepare at 1: 10.
Get purity and be 10% ginsenoside monomer Rg
3500 grams, ginsenoside monomer RH
15000 grams, panoxadiol's type saponin 5000 grams, above-mentioned ginsenoside monomer mixture is a pulverulence, adopts the gradient method mix homogeneously to get final product.In order to make this product have better therapeutic effect, can be added with purity and be 10% ginsenoside monomer Rg
55000 grams, 10% ginsenoside monomer RH
25000 grams.
In product, be added with Chinese medicine extract such as pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, better to treatment insufficiency of kidney-YANG ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 500 grams and the said goods mix homogeneously.
In product, be added with Chinese medicine extract such as the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, better to treatment deficiency of spleen-YANG type ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 500 grams and the said goods mix homogeneously.
Adopt common pharmaceutical technology that said mixture is made oral liquid or buccal tablet or electuary or tablet or drop pill or capsule or close ball.
The specific embodiment 3:
Get purity and be 10% ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin carries out compatibility and mixes, its weight ratio is pressed ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: 5, ginsenoside monomer Rg
3: panoxadiol's type saponin is to prepare at 1: 6.
Get purity and be 10% ginsenoside monomer Rg
3500 grams, ginsenoside monomer RH
12500 grams, panoxadiol's type saponin 3000 grams, above-mentioned ginsenoside monomer mixture is a pulverulence, adopts the gradient method mix homogeneously to get final product.In order to make this product have better therapeutic effect, can be added with purity and be 10% ginsenoside monomer Rg
52000 grams, 10% ginsenoside monomer RH
24000 grams.
In product, be added with Chinese medicine extract such as pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, better to treatment insufficiency of kidney-YANG ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 250 grams and the said goods mix homogeneously.
In product, be added with Chinese medicine extract such as the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, better to treatment deficiency of spleen-YANG type ED effect.Described Chinese medicine extract is equal portions preparation, adopts traditional hot reflux extracting mode or the supercritical mode of getting of quenching that Chinese medicine is extracted.Get the dry Powdered Chinese medicine extract in back of 150 grams and the said goods mix homogeneously.
Adopt common pharmaceutical technology that said mixture is made oral liquid or buccal tablet or electuary or tablet or drop pill or capsule or close ball.
Example 1: Zhang Deyu, the man, nineteen twenty-four life on October 20 was suffered from prostatosis 20 years, urinated 6-7 time every night, took this product, after 5 days, urinated 2-3 time every night, after the week, urinated every night 1 time.Through 1 month take, prostatic disorder disappeared at present, and health is good, and the soreness of the waist and knees disease disappears for many years simultaneously.
Example 2: Yang Huiling, the woman, nineteen fifty-three life on October 3 was suffered from urinary incontinence disease 2 years, took this product after one week, transference cure, health is good.
Example 3: single king and younger brother, the woman, nineteen forty-three life on June 1 was suffered from hyposexuality disease 10 years, took this product after one month, and hyposexuality disease changes, and vaginal secretions increases, and lubricious, health is good.
Example 4: Dan Shiqi, the man, life on January 17 in 1933 was suffered from prostate disease 10 years, urinated 3-4 time every night, and no sexual function is taken this product after one week, urinates 1-2 time every night, and prostate gland symptoms disappears after one month, and the sexual function performance is good.
Claims (5)
1, a kind of product of ginsenoside monomer compatibility sexual function improvement, it is characterized in that: it comprises ginsenoside monomer Rg
3, ginsenoside monomer RH
1, panoxadiol's type saponin, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer RH
1Be 1: (0.1-10),
Ginsenoside monomer Rg
3: panoxadiol's type saponin is 1: (0.1-10).
2, the product of ginsenoside monomer compatibility sexual function improvement according to claim 1, it is characterized in that: it also comprises ginsenoside monomer Rg
5, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer Rg
5Be 1: (0.1-10).
3, the product of ginsenoside monomer compatibility sexual function improvement according to claim 1 and 2, it is characterized in that: it also comprises ginsenoside monomer RH
2, its weight proportion is as follows:
Ginsenoside monomer Rg
3: ginsenoside monomer RH
2Be 1: (0.1-10).
4, the product of ginsenoside monomer compatibility sexual function improvement according to claim 3, it is characterized in that: it also comprises Chinese medicine extract, described Chinese medicine is: pubeseent epimedium herb, Fructus Lycii, the Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae Preparata, Radix Et Caulis Acanthopanacis Senticosi, each Chinese medicine extract is equal portions preparation, ginsenoside monomer Rg
3As follows with the weight proportion of Chinese medicine extract:
Ginsenoside monomer Rg
3: Chinese medicine extract is 1: (0.1-10).
5, the product of ginsenoside monomer compatibility sexual function improvement according to claim 3, it is characterized in that: it also comprises Chinese medicine extract, described Chinese medicine is: the Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, each Chinese medicine extract are equal portions preparation, ginsenoside monomer Rg
3As follows with the weight proportion of Chinese medicine extract:
Ginsenoside monomer Rg
3: Chinese medicine extract is 1: (0.1-10).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021607915A CN1191071C (en) | 2002-12-28 | 2002-12-28 | Product of ginsenoside for improving sextual function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021607915A CN1191071C (en) | 2002-12-28 | 2002-12-28 | Product of ginsenoside for improving sextual function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1425382A CN1425382A (en) | 2003-06-25 |
| CN1191071C true CN1191071C (en) | 2005-03-02 |
Family
ID=4753481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021607915A Expired - Lifetime CN1191071C (en) | 2002-12-28 | 2002-12-28 | Product of ginsenoside for improving sextual function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1191071C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264096B (en) * | 2007-03-12 | 2011-11-09 | 中国医学科学院药物研究所 | Use of ginsenoside Rg1 in preparing spermatogenic product |
| US10383904B2 (en) * | 2013-04-02 | 2019-08-20 | Amorepacific Corporation | Composition for improving health and quality of life of women containing ginseng berry extract |
-
2002
- 2002-12-28 CN CNB021607915A patent/CN1191071C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1425382A (en) | 2003-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1317027C (en) | Chinese medicine for treating depression | |
| CN1286518C (en) | Chinese medicinal prescription for treating gastropathy | |
| CN100396315C (en) | Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN102274417B (en) | Chinese prepared medicament for treating aplastic anemia | |
| CN1191071C (en) | Product of ginsenoside for improving sextual function | |
| CN1857697A (en) | Compound Chinese medicine Anxuekang and its preparing method | |
| CN101757444A (en) | Orally administrated medicine for Chinese traditional treatment of thyroid nodule | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN1265818C (en) | Leech capsule | |
| CN102488783A (en) | Symptom Chinese patent medicine for blood deficiency | |
| CN102335283B (en) | Snake medicinal wine for removing wind-dampness | |
| CN100502925C (en) | Antihyperglycemic hepatoprotective agent and its preparation method | |
| CN1211426A (en) | Medicine for treating diabetes | |
| CN1212121C (en) | Product of ginsenoside for curing hepatitis | |
| CN1060087C (en) | Traditional Chinese medicine extract tablet and preparation method therefor | |
| CN101884747B (en) | Traditional Chinese medicine for treating chronic nephritis | |
| CN102233004B (en) | Drug for treating liver diseases | |
| CN1108952A (en) | Xiaokelin capsule for diabetes | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1255166C (en) | Pure Chinese herbal medicine formulation for treating nephritis | |
| CN1425381A (en) | Product of ginsenoside for curing cancer | |
| CN1557365A (en) | Medicine | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN1103599C (en) | Chenxia medicament for relieving asthma and its pren. tech. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN JIFUSHEN BIOLOGICAL DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: YANG SHULING Effective date: 20100903 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 116021 2-3-2, NO.21, FUGUO STREET, SHAHEKOU DISTRICT, DALIAN CITY, LIAONING PROVINCE TO: 132000 19/F, HUOJU BUILDING, NO.6, SHENZHEN STREET, HIGH-TECH. ZONE, JILIN CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100903 Address after: 19, Torch Hotel, 6 Shenzhen street, 132000, Jilin hi tech Development Zone Patentee after: JILIN JIFUSHEN BIOLOGICAL DEVELOPMENT Co.,Ltd. Address before: 116021, 2-3-2, 21 Wells Fargo street, Shahekou District, Liaoning, Dalian Patentee before: Yang Shuling |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Product of ginsenoside for improving sextual function Effective date of registration: 20101123 Granted publication date: 20050302 Pledgee: Jilin credit guarantee investment Co.,Ltd. Pledgor: JILIN JIFUSHEN BIOLOGICAL DEVELOPMENT Co.,Ltd. Registration number: 2010990000973 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140417 Granted publication date: 20050302 Pledgee: Jilin credit guarantee investment Co.,Ltd. Pledgor: JILIN JIFUSHEN BIOLOGICAL DEVELOPMENT Co.,Ltd. Registration number: 2010990000973 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050302 |
|
| CX01 | Expiry of patent term | ||
| DD01 | Delivery of document by public notice |
Addressee: An Tao Document name: Notice of termination upon expiration of patent right |
|
| DD01 | Delivery of document by public notice |